CIM Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

CIM Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,648	Closed	-$233K	–	332
2021 Q2	$233K	Buy	+1,648	New	+$186K	0.07%	264
2020 Q4	–	Sell	-2,053	Closed	-$200K	–	305
2020 Q3	$200K	Buy	2,053 +29	+1%	+$3.62K	0.08%	239
2020 Q2	$316K	Buy	+2,024	New	+$308K	0.13%	163

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CIM Investment Management's RETA Position: Q3 2021 in Review

CIM Investment Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 1,648 shares — an estimated $233K sold.

CIM Investment Management first reported a position in RETA in Q2 2020 and held it in 3 quarters. The position peaked at $316K in Q2 2020. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

CIM Investment Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
CIM Investment Management sold 1,648 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $233K.
CIM Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 3 quarters.
CIM Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $316K in Q2 2020.
181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on CIM Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.